Rituximab for rheumatoid arthritis-related interstitial lung disease: A systematic review and meta-analysis.

Tarun Krishna Boppana Tarun Krishna Boppana Karan Madan Anant Mohan Vijay Hadda Randeep Guleria

Published in: Archives of rheumatology (2024)

Treatment with rituximab in RA-ILD was associated with a significant improvement in %-predicted FVC, as well as stabilization or improvement in ILD after one year of treatment.

Keyphrases

interstitial lung disease
rheumatoid arthritis
systemic sclerosis
idiopathic pulmonary fibrosis
disease activity
hodgkin lymphoma
ankylosing spondylitis